Special Survey of Production of Insulin Aspart Specific Antibody

Novo Nordisk A/S204 enrolled

Overview

This study is conducted in Japan. The aim of this study is to collect data of production of insulin aspart specific antibody under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

204

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diabetes requiring insulin therapy Exclusion Criteria: * Patients who had a treatment history of NovoRapid® (insulin aspart)

Locations (1)

Unnamed facility

Tokyo, Japan

Outcomes

Primary Outcomes

Antibody titre findings

Secondary Outcomes

Hypoglycemic events

Adverse events

HbA1c (glycosylated haemoglobin)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.